European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. / Raverot, Gerald; Burman, Pia; McCormack, Ann; Heaney, Anthony; Petersenn, Stephan; Popovic, Vera; Trouillas, Jacqueline; Dekkers, Olaf M.; European Society of Endocrinology.

I: European journal of endocrinology, Vol. 178, Nr. 1, 01.01.2018, s. G1-G24.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Raverot, G, Burman, P, McCormack, A, Heaney, A, Petersenn, S, Popovic, V, Trouillas, J, Dekkers, OM & European Society of Endocrinology 2018, 'European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas', European journal of endocrinology, vol. 178, nr. 1, s. G1-G24. https://doi.org/10.1530/EJE-17-0796

APA

CBE

Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM, European Society of Endocrinology. 2018. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European journal of endocrinology. 178(1):G1-G24. https://doi.org/10.1530/EJE-17-0796

MLA

Vancouver

Author

Raverot, Gerald ; Burman, Pia ; McCormack, Ann ; Heaney, Anthony ; Petersenn, Stephan ; Popovic, Vera ; Trouillas, Jacqueline ; Dekkers, Olaf M. ; European Society of Endocrinology. / European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. I: European journal of endocrinology. 2018 ; Vol. 178, Nr. 1. s. G1-G24.

RIS

TY - JOUR

T1 - European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

AU - Raverot, Gerald

AU - Burman, Pia

AU - McCormack, Ann

AU - Heaney, Anthony

AU - Petersenn, Stephan

AU - Popovic, Vera

AU - Trouillas, Jacqueline

AU - Dekkers, Olaf M.

AU - European Society of Endocrinology

PY - 2018/1/1

Y1 - 2018/1/1

N2 - BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present European Society of Endocrinology (ESE) guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas.METHODS: We decided upfront, while acknowledging that literature on aggressive pituitary tumours and carcinomas is scarce, to systematically review the literature according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The review focused primarily on first- and second-line treatment in aggressive pituitary tumours and carcinomas. We included 14 single-arm cohort studies (total number of patients = 116) most on temozolomide treatment (n = 11 studies, total number of patients = 106). A positive treatment effect was seen in 47% (95% CI: 36-58%) of temozolomide treated. Data from the recently performed ESE survey on aggressive pituitary tumours and carcinomas (165 patients) were also used as backbone for the guideline. SELECTED RECOMMENDATION: (i) Patients with aggressive pituitary tumours should be managed by a multidisciplinary expert team. (ii) Histopathological analyses including pituitary hormones and proliferative markers are needed for correct tumour classification. (iii) Temozolomide monotherapy is the first-line chemotherapy for aggressive pituitary tumours and pituitary carcinomas after failure of standard therapies; treatment evaluation after 3 cycles allows identification of responder and non-responder patients. (iv) In patients responding to first-line temozolomide, we suggest continuing treatment for at least 6 months in total. Furthermore, the guideline offers recommendations for patients who recurred after temozolomide treatment, for those who did not respond to temozolomide and for patients with systemic metastasis.

AB - BACKGROUND: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present European Society of Endocrinology (ESE) guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas.METHODS: We decided upfront, while acknowledging that literature on aggressive pituitary tumours and carcinomas is scarce, to systematically review the literature according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The review focused primarily on first- and second-line treatment in aggressive pituitary tumours and carcinomas. We included 14 single-arm cohort studies (total number of patients = 116) most on temozolomide treatment (n = 11 studies, total number of patients = 106). A positive treatment effect was seen in 47% (95% CI: 36-58%) of temozolomide treated. Data from the recently performed ESE survey on aggressive pituitary tumours and carcinomas (165 patients) were also used as backbone for the guideline. SELECTED RECOMMENDATION: (i) Patients with aggressive pituitary tumours should be managed by a multidisciplinary expert team. (ii) Histopathological analyses including pituitary hormones and proliferative markers are needed for correct tumour classification. (iii) Temozolomide monotherapy is the first-line chemotherapy for aggressive pituitary tumours and pituitary carcinomas after failure of standard therapies; treatment evaluation after 3 cycles allows identification of responder and non-responder patients. (iv) In patients responding to first-line temozolomide, we suggest continuing treatment for at least 6 months in total. Furthermore, the guideline offers recommendations for patients who recurred after temozolomide treatment, for those who did not respond to temozolomide and for patients with systemic metastasis.

U2 - 10.1530/EJE-17-0796

DO - 10.1530/EJE-17-0796

M3 - Article

VL - 178

SP - G1-G24

JO - European Journal of Endocrinology

T2 - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 1479-683X

IS - 1

ER -